How Has the Panuveitis Market Evolved Historically and What is its Current Size?
The panuveitis market has seen considerable growth due to a variety of factors.
• The market size for panuveitis has experienced a significant expansion lately. It is projected to escalate from $4.05 billion in 2024 to $4.47 billion in 2025, with a compound annual growth rate (CAGR) of 10.5%.
The historic progress in the market is ascribed to the widespread occurrence of autoimmune and infectious diseases, the expanding use of corticosteroids, the escalating adoption of biologics, the increasing demand for ophthalmic imaging, and rising investments in research into infectious causes.
What is the Forecasted Market Size and CAGR for the Panuveitis Market?
The panuveitis market is expected to maintain its strong growth trajectory in upcoming years.
• The panuveitis market is projected to experience significant expansion in the coming years, reaching a size of $6.58 billion in 2029 with a compound annual growth rate (CAGR) of 10.2%.
This upswing during the forecast period can be attributed to factors such as greater utilization of biologic therapies, an increased appetite for personalized medicine, a surge in diseases associated with uveitis, more substantial investment in eye-related research, and heightened awareness of the disease. Key trends forecasted for this period encompass escalated adoption of biologic therapies, the proliferation of sustained-release drug delivery systems, wider implementation of personalized medicine strategies, progress in AI-facilitated diagnosis and treatment, and a growing tendency towards minimally invasive surgical procedures.
What Key Factors and Trends Are Driving The Growth Panuveitis Market?
Progressive prevalence of autoimmune maladies is anticipated to stimulate the panuveitis market's growth. These disorders occur when the immune system mistakenly attacks and deteriorates the body's own healthy cells and tissues. The upward trend of these diseases is attributable to factors like genetic predispositions combined with environmental aspects such as pollution, dietary shifts, and increased exposure to certain infections and stressors leading to immune system instability. Autoimmune maladies fuel panuveitis treatment advancements through the promotion of research in immune system modulation, as a significant number of panuveitis cases stem from autoimmune actions. For example, the University of Oxford, a research university in the UK, reported in May 2023 that autoimmune disorders impact 10% of the global population, with 13% of females and 7% of males affected. Consequently, the escalating prevalence of autoimmune disorders is propelling the panuveitis market's expansion.
What Are The Market Segments In The Panuveitis Market?
The panuveitis market covered in this report is segmented –
1) By Type: Infectious Panuveitis, Non-Infectious Panuveitis
2) By Treatment: Pharmacological, Surgical, Phototherapy
3) By Route Of Administration: Oral, Intravitreal, Topical
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Infectious Panuveitis: Bacterial Panuveitis, Viral Panuveitis, Fungal Panuveitis, Parasitic Panuveitis
2) By Non-Infectious Panuveitis: Autoimmune-Related Panuveitis, Idiopathic Panuveitis, Drug-Induced Panuveitis
Pre-Book The Panuveitis Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Panuveitis Market?
Leading enterprises in the panuveitis market are directing their resources towards the creation of innovative slow-release intravitreal injection formulations to enhance patient satisfaction and results. This type of injectable formulation is a method for administering medication that continuously releases the drug into the eye's vitreous humor, ensuring a sustained therapeutic effect and lessening the frequency of dose administration. For example, Tarsier Pharma, a clinical-stage company based in Israel, revealed their latest project in August 2022: TRS02, a potential immunomodulator geared towards treating retinal diseases. This ground-breaking treatment is designed to address several issues related to the rear of the eye, marked by root inflammatory pathologies like panuveitis (posterior uveitis) and diabetic macular edema. TRS02 has been developed utilizing Tarsier's own exclusive technology platform and is currently moving forward towards an investigational new drug (IND) submission, subsequent to successful preclinical objectives.
Who Are the Key Players In The Panuveitis Market?
Major companies operating in the panuveitis market are:
• Pfizer Inc.
• AbbVie
• Boehringer Ingelheim International GmbH
• Amgen
• Teva Pharmaceuticals
• Sandoz
• Organon group of companies
• Zydus Lifesciences Ltd.
• Mallinckrodt plc
• Alvotech
• EyePoint Pharmaceuticals Inc.
• Affibody Medical AB
• Alumis Inc.
• Fujifilm Kyowa Kirin Biologics Co. Ltd.
• Revolo Biotherapeutics Ltd.
• Tarsier Pharma
• Priovant Therapeutics Inc.
• Mylan N.V.
• Clearside Biomedical Inc.
• pSivida Corp.
What Are The Regional Insights Into The Panuveitis Market?
North America was the largest region in the panuveitis market in 2024. The regions covered in the panuveitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
